Novabay Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Stablecoin Development Corporation reported significant shifts in its financial statements for Q2 2026, driven by digital asset holdings and warrant liability adjustments, alongside a strategic pivot.
NovaBay Pharmaceuticals, Inc. reported a net income of $4.455 million for the nine months ended September 30, 2025, driven by divestitures, and announced a strategic pivot towards blockchain-based assets while regaining NYSE American compliance.
NovaBay Pharmaceuticals reports a net income of $5.7 million for the first half of 2025 driven by asset divestitures, as it evaluates strategic options including potential dissolution.
10-Q: NovaBay Pharmaceuticals Reports Q1 2025 Results, Highlights Strategic Shift After Asset Divestitures
NovaBay Pharmaceuticals reports a net income of $7.67 million for Q1 2025, driven by gains from asset divestitures, while the company evaluates strategic options including a potential dissolution.
NovaBay Pharmaceuticals reports its Q3 2024 results, highlighting a strategic shift towards a potential asset sale and dissolution, while navigating financial challenges.
NovaBay Pharmaceuticals announced its second quarter 2024 results, highlighting the completion of the DERMAdoctor divestiture and a focus on its core eyecare and wound care segments.
NovaBay Pharmaceuticals reported its first quarter 2024 results, including a net loss of $3.2 million, and completed the sale of its DERMAdoctor subsidiary.